Ainos, Inc. (AIMD)
USD 0.52
(-1.9%)
USD 0.52
(-1.9%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -13.77 Million USD | 1.9% |
| 2022 | -14.03 Million USD | -259.48% |
| 2021 | -3.9 Million USD | -167.3% |
| 2020 | -1.46 Million USD | 7.67% |
| 2019 | -1.58 Million USD | -18.19% |
| 2018 | -1.33 Million USD | -116.83% |
| 2017 | -617.37 Thousand USD | 7.85% |
| 2016 | -669.98 Thousand USD | -28.38% |
| 2015 | -521.87 Thousand USD | 16.18% |
| 2014 | -622.6 Thousand USD | 0.0% |
| 2013 | -622.6 Thousand USD | 4.34% |
| 2012 | -650.84 Thousand USD | 50.46% |
| 2011 | -1.31 Million USD | -359.48% |
| 2010 | 506.31 Thousand USD | 117.04% |
| 2009 | -2.97 Million USD | -54.5% |
| 2008 | -1.92 Million USD | 23.26% |
| 2007 | -2.5 Million USD | 9.78% |
| 2006 | -2.77 Million USD | -315.19% |
| 2005 | -669.01 Thousand USD | -12.4% |
| 2004 | -595.2 Thousand USD | -457.2% |
| 2003 | 166.63 Thousand USD | 123.61% |
| 2002 | -705.82 Thousand USD | -46.56% |
| 2001 | -481.6 Thousand USD | 85.82% |
| 2000 | -3.39 Million USD | 44.51% |
| 1999 | -6.11 Million USD | -162.28% |
| 1998 | -2.33 Million USD | 5.6% |
| 1997 | -2.47 Million USD | -52.72% |
| 1996 | -1.61 Million USD | -439.4% |
| 1995 | -300 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.19 Million USD | 3.61% |
| 2024 Q1 | -3.31 Million USD | 44.05% |
| 2023 Q1 | -2.53 Million USD | -18.81% |
| 2023 Q3 | -2.97 Million USD | -26.65% |
| 2023 Q4 | -5.92 Million USD | -99.09% |
| 2023 FY | -13.77 Million USD | 1.9% |
| 2023 Q2 | -2.34 Million USD | 7.39% |
| 2022 Q1 | -2.11 Million USD | -46.51% |
| 2022 Q3 | -7.82 Million USD | -298.28% |
| 2022 Q4 | -2.13 Million USD | 72.7% |
| 2022 FY | -14.03 Million USD | -259.48% |
| 2022 Q2 | -1.96 Million USD | 7.23% |
| 2021 Q2 | -749.77 Thousand USD | -40.41% |
| 2021 Q1 | -534 Thousand USD | -19.07% |
| 2021 Q3 | -1.16 Million USD | -54.73% |
| 2021 Q4 | -1.44 Million USD | -24.54% |
| 2021 FY | -3.9 Million USD | -167.3% |
| 2020 Q3 | -323.28 Thousand USD | -7.06% |
| 2020 Q4 | -448.49 Thousand USD | -38.73% |
| 2020 Q2 | -301.96 Thousand USD | 19.88% |
| 2020 Q1 | -376.87 Thousand USD | -1.83% |
| 2020 FY | -1.46 Million USD | 7.67% |
| 2019 Q1 | -391.38 Thousand USD | 22.4% |
| 2019 Q2 | -453.51 Thousand USD | -15.87% |
| 2019 Q4 | -370.11 Thousand USD | -1.07% |
| 2019 FY | -1.58 Million USD | -18.19% |
| 2019 Q3 | -366.21 Thousand USD | 19.25% |
| 2018 Q2 | -331.79 Thousand USD | -72.43% |
| 2018 FY | -1.33 Million USD | -116.83% |
| 2018 Q1 | -192.43 Thousand USD | 7.76% |
| 2018 Q3 | -310.03 Thousand USD | 6.56% |
| 2018 Q4 | -504.37 Thousand USD | -62.68% |
| 2017 Q2 | 13.02 Thousand USD | 106.89% |
| 2017 Q3 | -232.8 Thousand USD | -1887.5% |
| 2017 FY | -617.37 Thousand USD | 7.85% |
| 2017 Q1 | -188.97 Thousand USD | 18.84% |
| 2017 Q4 | -208.62 Thousand USD | 10.39% |
| 2016 Q3 | -179.26 Thousand USD | -31.6% |
| 2016 Q1 | -121.64 Thousand USD | 36.9% |
| 2016 FY | -669.98 Thousand USD | -28.38% |
| 2016 Q4 | -232.84 Thousand USD | -29.89% |
| 2016 Q2 | -136.22 Thousand USD | -11.99% |
| 2015 FY | -521.87 Thousand USD | 16.18% |
| 2015 Q4 | -192.78 Thousand USD | -68.89% |
| 2015 Q3 | -114.14 Thousand USD | -10.99% |
| 2015 Q2 | -102.84 Thousand USD | 8.24% |
| 2015 Q1 | -112.08 Thousand USD | -103.4% |
| 2014 Q1 | -175.06 Thousand USD | -37.43% |
| 2014 FY | -622.6 Thousand USD | 0.0% |
| 2014 Q4 | 3.3 Million USD | 3264.18% |
| 2014 Q3 | -104.33 Thousand USD | 44.17% |
| 2014 Q2 | -186.88 Thousand USD | -6.76% |
| 2013 FY | -622.6 Thousand USD | 4.34% |
| 2013 Q2 | -193.11 Thousand USD | -3.51% |
| 2013 Q1 | -186.55 Thousand USD | -33.89% |
| 2013 Q4 | -127.37 Thousand USD | -10.23% |
| 2013 Q3 | -115.55 Thousand USD | 40.16% |
| 2012 Q3 | -146.77 Thousand USD | -14.11% |
| 2012 Q2 | -128.62 Thousand USD | 45.52% |
| 2012 Q1 | -236.11 Thousand USD | -2.48% |
| 2012 Q4 | -139.33 Thousand USD | 5.07% |
| 2012 FY | -650.84 Thousand USD | 50.46% |
| 2011 Q4 | -230.41 Thousand USD | 56.92% |
| 2011 Q1 | -220.25 Thousand USD | -132.68% |
| 2011 Q3 | -534.8 Thousand USD | -62.9% |
| 2011 Q2 | -328.3 Thousand USD | -49.06% |
| 2011 FY | -1.31 Million USD | -359.48% |
| 2010 Q4 | 673.98 Thousand USD | 460.36% |
| 2010 Q1 | -235.44 Thousand USD | -121.13% |
| 2010 Q2 | 526.37 Thousand USD | 323.56% |
| 2010 FY | 506.31 Thousand USD | 117.04% |
| 2010 Q3 | 120.27 Thousand USD | -77.15% |
| 2009 Q1 | -563.59 Thousand USD | -35.77% |
| 2009 Q4 | 1.11 Million USD | 202.23% |
| 2009 Q3 | -1.09 Million USD | 55.17% |
| 2009 Q2 | -2.43 Million USD | -331.5% |
| 2009 FY | -2.97 Million USD | -54.5% |
| 2008 Q3 | -331.94 Thousand USD | 38.06% |
| 2008 Q4 | -415.12 Thousand USD | -25.06% |
| 2008 Q2 | -535.91 Thousand USD | 16.28% |
| 2008 FY | -1.92 Million USD | 23.26% |
| 2008 Q1 | -640.09 Thousand USD | -22.45% |
| 2007 FY | -2.5 Million USD | 9.78% |
| 2007 Q4 | -522.74 Thousand USD | 16.56% |
| 2007 Q3 | -626.51 Thousand USD | -2.44% |
| 2007 Q2 | -611.6 Thousand USD | 17.93% |
| 2007 Q1 | -745.2 Thousand USD | -49.8% |
| 2006 Q3 | -784.7 Thousand USD | 0.52% |
| 2006 Q1 | -771 Thousand USD | -211.68% |
| 2006 FY | -2.77 Million USD | -315.19% |
| 2006 Q4 | -497.46 Thousand USD | 36.6% |
| 2006 Q2 | -788.8 Thousand USD | -2.31% |
| 2005 Q3 | -147.17 Thousand USD | -91.99% |
| 2005 Q1 | -197.79 Thousand USD | -36.62% |
| 2005 FY | -669.01 Thousand USD | -12.4% |
| 2005 Q2 | -76.65 Thousand USD | 61.24% |
| 2005 Q4 | -247.37 Thousand USD | -68.08% |
| 2004 Q2 | -200.91 Thousand USD | -42.51% |
| 2004 Q3 | -108.52 Thousand USD | 45.98% |
| 2004 Q1 | -140.98 Thousand USD | 26.39% |
| 2004 FY | -595.2 Thousand USD | -457.2% |
| 2004 Q4 | -144.78 Thousand USD | -33.41% |
| 2003 Q3 | 616.47 Thousand USD | 381.54% |
| 2003 FY | 166.63 Thousand USD | 123.61% |
| 2003 Q4 | -191.53 Thousand USD | -131.07% |
| 2003 Q1 | -39.34 Thousand USD | 71.27% |
| 2003 Q2 | -218.96 Thousand USD | -456.52% |
| 2002 Q4 | -136.96 Thousand USD | 6.35% |
| 2002 FY | -705.82 Thousand USD | -46.56% |
| 2002 Q3 | -146.25 Thousand USD | 20.24% |
| 2002 Q2 | -183.37 Thousand USD | 23.35% |
| 2002 Q1 | -239.23 Thousand USD | 13.28% |
| 2001 Q2 | -154.91 Thousand USD | 29.85% |
| 2001 FY | -481.6 Thousand USD | 85.82% |
| 2001 Q3 | 170.03 Thousand USD | 209.76% |
| 2001 Q4 | -275.88 Thousand USD | -262.25% |
| 2001 Q1 | -220.83 Thousand USD | 57.8% |
| 2000 Q2 | -1.26 Million USD | -1.61% |
| 2000 Q3 | -369.61 Thousand USD | 70.69% |
| 2000 Q1 | -1.24 Million USD | 0.0% |
| 2000 FY | -3.39 Million USD | 44.51% |
| 2000 Q4 | -523.34 Thousand USD | -41.59% |
| 1999 Q1 | -2 Million USD | -216.06% |
| 1999 FY | -6.11 Million USD | -162.28% |
| 1999 Q2 | -900 Thousand USD | 55.0% |
| 1998 Q3 | -500 Thousand USD | 16.67% |
| 1998 Q1 | -600 Thousand USD | 22.2% |
| 1998 Q4 | -632.8 Thousand USD | -26.56% |
| 1998 FY | -2.33 Million USD | 5.6% |
| 1998 Q2 | -600 Thousand USD | 0.0% |
| 1997 FY | -2.47 Million USD | -52.72% |
| 1997 Q1 | -500 Thousand USD | 3.51% |
| 1997 Q2 | -600 Thousand USD | -20.0% |
| 1997 Q3 | -600 Thousand USD | 0.0% |
| 1997 Q4 | -771.25 Thousand USD | -28.54% |
| 1996 Q2 | -200 Thousand USD | 0.0% |
| 1996 Q3 | -900 Thousand USD | -350.0% |
| 1996 Q4 | -518.18 Thousand USD | 42.42% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | -1.61 Million USD | -439.4% |
| 1995 FY | -300 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 90.594% |
| Alkermes plc | 355.75 Million USD | 103.871% |
| Agenus Inc. | -245.76 Million USD | 94.397% |
| Aptorum Group Limited | -2.82 Million USD | -387.514% |
| Ardelyx, Inc. | -66.06 Million USD | 79.157% |
| Dyadic International, Inc. | -6.79 Million USD | -102.643% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -1371.213% |
| Lantern Pharma Inc. | -15.96 Million USD | 13.727% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 27.633% |
| Novavax, Inc. | -545.06 Million USD | 97.474% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 76.377% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 81.338% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 25.75% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -37.899% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 76.653% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 96.314% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 43.423% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 63.121% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 91.633% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 81.225% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 32.135% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 77.88% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 57.61% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 89.607% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 96.872% |
| AlloVir, Inc. | -190.41 Million USD | 92.768% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 93.292% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 51.601% |
| Bicycle Therapeutics plc | -180.66 Million USD | 92.378% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 92.309% |
| ChromaDex Corporation | -4.93 Million USD | -178.869% |
| Chimerix, Inc. | -82.09 Million USD | 83.226% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 69.127% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 86.509% |
| CRISPR Therapeutics AG | -153.61 Million USD | 91.035% |
| Precision BioSciences, Inc. | -61.31 Million USD | 77.543% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 91.443% |
| Fortress Biotech, Inc. | -60.63 Million USD | 77.29% |
| Fortress Biotech, Inc. | -60.63 Million USD | 77.29% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 83.12% |
| ImmuCell Corporation | -5.77 Million USD | -138.468% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 87.809% |
| Immix Biopharma, Inc. | -15.42 Million USD | 10.732% |
| Incyte Corporation | 597.59 Million USD | 102.304% |
| Innoviva, Inc. | 179.72 Million USD | 107.662% |
| IO Biotech, Inc. | -86.08 Million USD | 84.003% |
| Jaguar Health, Inc. | -41.3 Million USD | 66.657% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 90.999% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 126.404% |
| ContextLogic Inc. | -317 Million USD | 95.656% |
| MiMedx Group, Inc. | 67.43 Million USD | 120.419% |
| MEI Pharma, Inc. | 17.77 Million USD | 177.458% |
| NextCure, Inc. | -62.72 Million USD | 78.045% |
| Onconetix, Inc. | -37.4 Million USD | 63.19% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 65.119% |
| Opthea Limited | -220.24 Million USD | 93.748% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 73.083% |
| Vaxcyte, Inc. | -402.26 Million USD | 96.577% |
| PDS Biotechnology Corporation | -42.94 Million USD | 67.932% |
| Precigen, Inc. | -95.9 Million USD | 85.641% |
| Pharming Group N.V. | -10.54 Million USD | -30.551% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 93.169% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 43.892% |
| PureTech Health plc | -65.69 Million USD | 79.039% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 45.118% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 93.511% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 43.423% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 94.659% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 49.444% |
| Acelyrin, Inc. | -381.64 Million USD | 96.392% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -109689.439% |
| Summit Therapeutics Inc. | -614.92 Million USD | 97.761% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 59.618% |
| Senti Biosciences, Inc. | -92.91 Million USD | 85.18% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 86.847% |
| Elevation Oncology, Inc. | -45.7 Million USD | 69.87% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 60.812% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | -5.345% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -105.992% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 53.101% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -61.987% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 76.057% |
| Seer, Inc. | -86.27 Million USD | 84.039% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 79.445% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 79.061% |
| ESSA Pharma Inc. | -26.58 Million USD | 48.197% |
| GlycoMimetics, Inc. | -36.89 Million USD | 62.681% |
| GT Biopharma, Inc. | -7.59 Million USD | -81.263% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 94.295% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 73.48% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 119.284% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 74.697% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 71.965% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -38.429% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 97.596% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -283.795% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 73.03% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 94.393% |
| Aptose Biosciences Inc. | -51.2 Million USD | 73.108% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 85.991% |
| Soligenix, Inc. | -6.14 Million USD | -124.249% |
| Century Therapeutics, Inc. | -136.67 Million USD | 89.924% |
| Kura Oncology, Inc. | -152.63 Million USD | 90.978% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 84.565% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -30.675% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 2535.24% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -2320.132% |
| Autolus Therapeutics plc | -208.38 Million USD | 93.392% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 80.847% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 80.549% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 36.448% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 93.887% |
| GRI Bio, Inc. | -13.03 Million USD | -5.627% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -233.058% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 88.902% |
| IGM Biosciences, Inc. | -246.41 Million USD | 94.412% |
| INmune Bio, Inc. | -30 Million USD | 54.11% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 87.545% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 67.364% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 13.727% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 12.817% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 76.928% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 86.388% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 95.013% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 94.211% |
| Verastem, Inc. | -87.36 Million USD | 84.238% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 74.587% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 91.465% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 88.196% |
| Histogen Inc. | -10.62 Million USD | -29.654% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 3.613% |
| Surrozen, Inc. | -43.04 Million USD | 68.007% |
| Organovo Holdings, Inc. | -14.67 Million USD | 6.138% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -170.699% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 73.69% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 45.491% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 48.881% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -64.777% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 90.886% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 71.854% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 53.674% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -32.184% |
| Apollomics, Inc. | -172.6 Million USD | 92.022% |
| Amarin Corporation plc | -59.11 Million USD | 76.704% |
| Mesoblast Limited | -87.95 Million USD | 84.344% |
| Turnstone Biologics Corp. | -55.2 Million USD | 75.053% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 90.63% |
| Synaptogenix, Inc. | -6.03 Million USD | -128.046% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 15.039% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 82.35% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -187.397% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -63.892% |
| Exelixis, Inc. | 207.76 Million USD | 106.628% |
| Better Therapeutics, Inc. | -39.76 Million USD | 65.366% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 90.434% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 97.395% |
| NLS Pharmaceutics AG | -12.17 Million USD | -13.133% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -76.666% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 55.216% |
| Gritstone bio, Inc. | -138.49 Million USD | 90.057% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 78.639% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -244.268% |
| Avid Bioservices, Inc. | -140.75 Million USD | 90.217% |
| Insmed Incorporated | -749.56 Million USD | 98.163% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 9.342% |
| MediWound Ltd. | -6.71 Million USD | -105.041% |
| OmniAb, Inc. | -50.61 Million USD | 72.796% |
| Alector, Inc. | -130.39 Million USD | 89.439% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 87.891% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 73.44% |
| Zai Lab Limited | -334.62 Million USD | 95.885% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 95.75% |
| Aura Biosciences, Inc. | -76.4 Million USD | 81.978% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 94.131% |
| Immunic, Inc. | -93.61 Million USD | 85.29% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 89.867% |
| Veracyte, Inc. | -74.4 Million USD | 81.492% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -79.408% |
| FibroGen, Inc. | -284.23 Million USD | 95.155% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 47.505% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -96.669% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 26.88% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 103.32% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 38.947% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 127.949% |
| TG Therapeutics, Inc. | 12.67 Million USD | 208.669% |
| Galecto, Inc. | -38.34 Million USD | 64.092% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 27.009% |
| Fortrea Holdings Inc. | -3.4 Million USD | -305.016% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 89.127% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 20.909% |
| XBiotech Inc. | -24.55 Million USD | 43.924% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 78.639% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 78.03% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 86.009% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 35.733% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 75.05% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 97.73% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 79.825% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -24086.864% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 93.921% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 38.159% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 93.732% |
| NexImmune, Inc. | -32.34 Million USD | 57.425% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -160.482% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 1.96% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.348% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 43.146% |
| Scopus BioPharma Inc. | -11.6 Million USD | -18.611% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 88.21% |
| Pluri Inc. | -20.88 Million USD | 34.074% |
| Prothena Corporation plc | -147.02 Million USD | 90.634% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 87.907% |
| Celularity Inc. | -196.29 Million USD | 92.985% |
| Rallybio Corporation | -74.56 Million USD | 81.532% |
| Cue Biopharma, Inc. | -50.73 Million USD | 72.857% |
| MeiraGTx Holdings plc | -84.02 Million USD | 83.612% |
| Omeros Corporation | -117.81 Million USD | 88.312% |
| Humacyte, Inc. | -110.77 Million USD | 87.569% |
| Immunocore Holdings plc | -55.28 Million USD | 75.093% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 23.429% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 39.948% |
| Blueprint Medicines Corporation | -506.98 Million USD | 97.284% |
| CalciMedica, Inc. | -34.35 Million USD | 59.919% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 79.652% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 90.262% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 91.694% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 95.138% |
| Pulmatrix, Inc. | -14.12 Million USD | 2.482% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 60.874% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 83.336% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 97.138% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 86.869% |
| Cytokinetics, Incorporated | -526.24 Million USD | 97.383% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 61.817% |
| Nutriband Inc. | -5.48 Million USD | -151.044% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 65.931% |
| Vor Biopharma Inc. | -117.86 Million USD | 88.316% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 100.317% |
| Evogene Ltd. | -23.87 Million USD | 42.332% |
| ProKidney Corp. | -35.46 Million USD | 61.175% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 88.502% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -75.524% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 97.859% |
| CorMedix Inc. | -46.33 Million USD | 70.283% |
| BioLineRx Ltd. | -60.61 Million USD | 77.282% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 86.465% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 66.467% |
| Atai Life Sciences N.V. | -40.22 Million USD | 65.765% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 82.926% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 81.766% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 95.287% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 50.601% |
| MediciNova, Inc. | -8.57 Million USD | -60.655% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 88.83% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -64.388% |
| GeoVax Labs, Inc. | -25.96 Million USD | 46.969% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 94.244% |
| Biomea Fusion, Inc. | -117.25 Million USD | 88.256% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 97.802% |
| Mereo BioPharma Group plc | -29.46 Million USD | 53.266% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 91.009% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 93.423% |
| Absci Corporation | -110.56 Million USD | 87.545% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 54.327% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 86.344% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 94.163% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 197.774% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 92.864% |
| Allakos Inc. | -185.7 Million USD | 92.585% |
| Imunon, Inc. | -19.51 Million USD | 29.436% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 85.852% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 112.974% |
| BioAtla, Inc. | -123.46 Million USD | 88.846% |
| NLS Pharmaceutics AG | -12.17 Million USD | -13.133% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 14.352% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 95.792% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 62.731% |
| XOMA Corporation | -40.83 Million USD | 66.274% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 86.482% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 88.381% |
| aTyr Pharma, Inc. | -50.38 Million USD | 72.672% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 84.294% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 90.926% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 94.208% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 60.789% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -70.176% |
| Akari Therapeutics, Plc | -10 Million USD | -37.595% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -20353.842% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 104.89% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -106.613% |
| UroGen Pharma Ltd. | -102.24 Million USD | 86.532% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 87.105% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -77.063% |
| Orgenesis Inc. | -55.36 Million USD | 75.126% |
| Entera Bio Ltd. | -8.88 Million USD | -54.917% |
| GH Research PLC | -35.58 Million USD | 61.305% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 33.923% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 82.206% |
| Xencor, Inc. | -126.08 Million USD | 89.079% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -265.683% |
| Replimune Group, Inc. | -215.79 Million USD | 93.619% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 35.248% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 648.846% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -106.613% |
| Portage Biotech Inc. | -75.33 Million USD | 81.722% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -64.388% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 85.753% |
| OncoCyte Corporation | -27.78 Million USD | 50.432% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | -2.633% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | -23.819% |
| Purple Biotech Ltd. | -19.88 Million USD | 30.732% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -96.19% |
| scPharmaceuticals Inc. | -54.81 Million USD | 74.876% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 21.339% |
| HilleVax, Inc. | -123.56 Million USD | 88.856% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -36.248% |
| Tharimmune, Inc. | -9.31 Million USD | -47.767% |
| Genprex, Inc. | -30.86 Million USD | 55.378% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 94.163% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 54.242% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -672.758% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -160.017% |
| OKYO Pharma Limited | -16.82 Thousand USD | -81743.522% |
| Savara Inc. | -54.69 Million USD | 74.824% |
| Curis, Inc. | -47.41 Million USD | 70.956% |
| Daré Bioscience, Inc. | -30.16 Million USD | 54.344% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 10.842% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -147.271% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 53.813% |
| BeiGene, Ltd. | -881.7 Million USD | 98.438% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 35.331% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 96.844% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 82.559% |
| Erasca, Inc. | -125.04 Million USD | 88.987% |
| bluebird bio, Inc. | -211.91 Million USD | 93.502% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -175.384% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 108.214% |
| DBV Technologies S.A. | -72.72 Million USD | 81.065% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -175.384% |
| Moderna, Inc. | -4.71 Billion USD | 99.708% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 65.708% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -141.843% |
| Molecular Templates, Inc. | -8.12 Million USD | -69.505% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 77.197% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 87.639% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 89.826% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 71.263% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 90.263% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 92.843% |
| MacroGenics, Inc. | -9.05 Million USD | -52.026% |
| RenovoRx, Inc. | -10.23 Million USD | -34.583% |
| Adicet Bio, Inc. | -142.65 Million USD | 90.347% |
| Prime Medicine, Inc. | -198.13 Million USD | 93.05% |
| Aditxt, Inc. | -32.38 Million USD | 57.473% |
| Adagene Inc. | -18.94 Million USD | 27.318% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -88.335% |
| Quantum-Si incorporated | -95.96 Million USD | 85.65% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 88.431% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 5.537% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 110.406% |
| SciSparc Ltd. | -5.12 Million USD | -168.851% |
| Vericel Corporation | -3.18 Million USD | -332.764% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -11351.219% |
| Minerva Neurosciences, Inc. | -30 Million USD | 54.106% |
| Generation Bio Co. | -126.61 Million USD | 89.124% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 81.108% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 83.297% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 94.747% |
| Invivyd, Inc. | -198.64 Million USD | 93.068% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 95.973% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -58.527% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 160.381% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -39.463% |
| 2seventy bio, Inc. | -217.57 Million USD | 93.671% |
| ADMA Biologics, Inc. | -28.23 Million USD | 51.236% |
| Clene Inc. | -49.5 Million USD | 72.183% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 38.214% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 72.144% |
| GeoVax Labs, Inc. | -25.96 Million USD | 46.969% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 95.803% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 57.685% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 160.61% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 86.061% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 81.579% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 91.436% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 97.761% |
| Evaxion Biotech A/S | -22.12 Million USD | 37.76% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 82.944% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 93.117% |
| Trevena, Inc. | -40.28 Million USD | 65.821% |
| Surrozen, Inc. | -43.04 Million USD | 68.007% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 80.081% |
| Cingulate Inc. | -23.53 Million USD | 41.489% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -99.227% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 65.453% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -78.591% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 84.735% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 77.531% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 76.857% |
| Clearmind Medicine Inc. | -11.95 Million USD | -15.186% |
| Kronos Bio, Inc. | -112.67 Million USD | 87.778% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 80.099% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -542853.478% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 83.968% |
| Statera Biopharma, Inc. | -174.4 Million USD | 92.104% |
| ImmunityBio, Inc. | -583.19 Million USD | 97.639% |
| Korro Bio, Inc. | -81.17 Million USD | 83.035% |
| Kineta, Inc. | -14.09 Million USD | 2.33% |
| BioVie Inc. | -32.12 Million USD | 57.129% |
| Codexis, Inc. | -76.24 Million USD | 81.938% |
| Celularity Inc. | -196.29 Million USD | 92.985% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 93.581% |
| Celcuity Inc. | -63.77 Million USD | 78.409% |
| Virax Biolabs Group Limited | -6.73 Million USD | -104.507% |
| Cibus, Inc. | -267.62 Million USD | 94.855% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 65.852% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 61.547% |
| IN8bio, Inc. | -30 Million USD | 54.109% |
| Kodiak Sciences Inc. | -260.49 Million USD | 94.714% |
| Annexon, Inc. | -134.23 Million USD | 89.742% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 88.247% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 77.509% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 56.345% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 96.24% |
| Eyenovia, Inc. | -27.26 Million USD | 49.486% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 163.779% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -2473.934% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 81.977% |
| Arcellx, Inc. | -70.69 Million USD | 80.52% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 66.771% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 89.709% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 54.155% |
| Moolec Science SA | -51.78 Million USD | 73.41% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 73.706% |
| Geron Corporation | -184.12 Million USD | 92.521% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 67.193% |
| Royalty Pharma plc | 1.13 Billion USD | 101.213% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 89.871% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -54.868% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 35.177% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 91.978% |
| Humacyte, Inc. | -110.77 Million USD | 87.569% |
| Structure Therapeutics Inc. | -89.62 Million USD | 84.635% |
| 89bio, Inc. | -142.18 Million USD | 90.315% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 80.031% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -32.703% |
| Genelux Corporation | -28.29 Million USD | 51.336% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 52.622% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 92.225% |
| Notable Labs, Ltd. | -11.26 Million USD | -22.253% |
| Liquidia Corporation | -78.5 Million USD | 82.458% |
| Mustang Bio, Inc. | -51.6 Million USD | 73.314% |
| Immunovant, Inc. | -259.33 Million USD | 94.69% |
| Quantum-Si incorporated | -95.96 Million USD | 85.65% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 81.097% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 28.948% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 85.654% |
| Acasti Pharma Inc. | -12.85 Million USD | -7.139% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 38.683% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 13.727% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 92.45% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -220.132% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | -10.429% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 53.306% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 64.68% |
| PepGen Inc. | -78.62 Million USD | 82.486% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 53.742% |
| United Therapeutics Corporation | 984.8 Million USD | 101.398% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 38.138% |
| Solid Biosciences Inc. | -96.01 Million USD | 85.658% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -187.397% |
| Immuneering Corporation | -53.47 Million USD | 74.247% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -170.699% |
| Silo Pharma, Inc. | -3.7 Million USD | -272.108% |
| Belite Bio, Inc | -31.63 Million USD | 56.466% |
| XOMA Corporation | -40.83 Million USD | 66.274% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 74.67% |
| Bionomics Limited | -15.49 Billion USD | 99.911% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 83.604% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 52.771% |
| uniQure N.V. | -308.47 Million USD | 95.536% |
| Cassava Sciences, Inc. | -97.21 Million USD | 85.835% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -88.335% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 88.843% |
| Forte Biosciences, Inc. | -31.47 Million USD | 56.251% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -67.899% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 52.626% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -2473.934% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 47.505% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 16.466% |
| Altimmune, Inc. | -88.44 Million USD | 84.431% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 90.916% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 52.771% |
| Compugen Ltd. | -18.75 Million USD | 26.573% |
| Peak Bio, Inc. | -1259.26 USD | -1093442.954% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 70.096% |
| Benitec Biopharma Inc. | -21.75 Million USD | 36.69% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 95.935% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 83.4% |
| Zura Bio Limited | -60.36 Million USD | 77.186% |
| PolyPid Ltd. | -23.86 Million USD | 42.298% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 12.468% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 83.4% |
| Instil Bio, Inc. | -156.08 Million USD | 91.178% |
| argenx SE | -295.05 Million USD | 95.333% |
| Immunome, Inc. | -106.8 Million USD | 87.107% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 67.594% |
| Verona Pharma plc | -54.36 Million USD | 74.672% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 86.218% |
| Shattuck Labs, Inc. | -87.29 Million USD | 84.226% |
| CervoMed Inc. | -2.17 Million USD | -534.04% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 88.953% |
| Plus Therapeutics, Inc. | -13.31 Million USD | -3.414% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 68.384% |
| Moolec Science SA | -51.78 Million USD | 73.41% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -79536.618% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 89.808% |
| AnaptysBio, Inc. | -163.61 Million USD | 91.584% |
| Design Therapeutics, Inc. | -66.86 Million USD | 79.405% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 83.086% |
| NeurAxis, Inc. | -14.62 Million USD | 5.853% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 63.649% |
| Lumos Pharma, Inc. | -34.03 Million USD | 59.539% |
| Achilles Therapeutics plc | -69.66 Million USD | 80.233% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 86.218% |
| 180 Life Sciences Corp. | -19.93 Million USD | 30.923% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 557.677% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -542853.478% |
| Nutriband Inc. | -5.48 Million USD | -151.044% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 86.325% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 71.67% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 82.137% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 59.463% |
| MoonLake Immunotherapeutics | -36 Million USD | 61.756% |
| Palisade Bio, Inc. | -12.3 Million USD | -11.956% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 67.309% |
| Beam Therapeutics Inc. | -132.52 Million USD | 89.609% |
| Neurogene Inc. | -36.31 Million USD | 62.082% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 91.573% |
| AEON Biopharma, Inc. | -52.55 Million USD | 73.798% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 85.969% |
| Sesen Bio, Inc. | -19.88 Million USD | 30.746% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 80.763% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | -10.042% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 96.899% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 87.657% |
| Athira Pharma, Inc. | -117.67 Million USD | 88.298% |
| Vaccinex, Inc. | -20.25 Million USD | 32.001% |
| HCW Biologics Inc. | -24.99 Million USD | 44.905% |
| XOMA Corporation | -40.83 Million USD | 66.274% |
| Nektar Therapeutics | -276.05 Million USD | 95.012% |
| Arvinas, Inc. | -367.3 Million USD | 96.251% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -20353.842% |
| Merus N.V. | -154.93 Million USD | 91.112% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 85.866% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 56.124% |
| Rezolute, Inc. | -68.45 Million USD | 79.885% |
| Clene Inc. | -49.5 Million USD | 72.183% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 10.717% |
| BeyondSpring Inc. | -21.02 Million USD | 34.507% |
| Synlogic, Inc. | -57.28 Million USD | 75.96% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | -15.709% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -27.199% |
| Peak Bio, Inc. | -1259.26 USD | -1093442.954% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 63.149% |
| Krystal Biotech, Inc. | 10.93 Million USD | 225.966% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 90.377% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 95.764% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -198.131% |
| MannKind Corporation | -11.93 Million USD | -15.351% |
| Ikena Oncology, Inc. | -68.16 Million USD | 79.799% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 34.473% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 85.182% |
| Gossamer Bio, Inc. | -179.81 Million USD | 92.342% |
| CohBar, Inc. | -11.96 Million USD | -15.118% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 46.601% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 54.327% |
| Legend Biotech Corporation | -518.25 Million USD | 97.343% |
| Mural Oncology plc | -207.44 Million USD | 93.362% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 88.905% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 24.709% |
| Disc Medicine, Inc. | -76.42 Million USD | 81.983% |
| Champions Oncology, Inc. | -7.27 Million USD | -89.26% |
| REGENXBIO Inc. | -263.49 Million USD | 94.774% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | -29.751% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 71.012% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 63.746% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 86.252% |
| Vaxart, Inc. | -82.46 Million USD | 83.301% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 4225.846% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 63.32% |
| Cellectis S.A. | -101.05 Million USD | 86.374% |
| Longeveron Inc. | -21.41 Million USD | 35.691% |
| Repare Therapeutics Inc. | -93.79 Million USD | 85.319% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 97.431% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 80.651% |
| Revolution Medicines, Inc. | -436.36 Million USD | 96.844% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -109.565% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 55.325% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 80.139% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 78.727% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -40.358% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.38% |
| Denali Therapeutics Inc. | -145.22 Million USD | 90.518% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -11351.219% |
| Veru Inc. | -93.15 Million USD | 85.217% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 49.053% |
| Cingulate Inc. | -23.53 Million USD | 41.489% |
| Passage Bio, Inc. | -102.06 Million USD | 86.508% |
| Context Therapeutics Inc. | -23.96 Million USD | 42.537% |
| Exicure, Inc. | -16.91 Million USD | 18.585% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 92.711% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 63.535% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -111.616% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 92.543% |
| Nuvalent, Inc. | -126.21 Million USD | 89.09% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -30.953% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 84.15% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 54.916% |
| OmniAb, Inc. | -50.61 Million USD | 72.796% |
| Anew Medical, Inc. | 1.34 Million USD | 1122.977% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 14.175% |
| Lipocine Inc. | -16.35 Million USD | 15.787% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 79.259% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 78.374% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 67.364% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 71.292% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 30.56% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 97.457% |
| Ocugen, Inc. | -63.07 Million USD | 78.169% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 85.616% |
| Q32 Bio Inc. | -112.96 Million USD | 87.809% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 19.901% |
| Alumis Inc. Common Stock | -154.99 Million USD | 91.115% |
| Equillium, Inc. | -13.33 Million USD | -3.266% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 77.188% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -72.394% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 26.951% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 76.692% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 87.976% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 25.07% |
| Dominari Holdings Inc. | -22.88 Million USD | 39.819% |
| Edesa Biotech, Inc. | -8.37 Million USD | -64.436% |
| vTv Therapeutics Inc. | -20.25 Million USD | 31.997% |
| Bio-Techne Corporation | 168.1 Million USD | 108.192% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 96.089% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 110.687% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 88.697% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 63.703% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 87.775% |
| Nkarta, Inc. | -117.5 Million USD | 88.28% |
| BioCardia, Inc. | -11.57 Million USD | -19.009% |
| Iterum Therapeutics plc | -38.37 Million USD | 64.112% |